Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
J. Clin. Invest. Jehonathan H. Pinthus, et al. 114:1774 doi:10.1172/JCI22284 [Go to this article.]

Figure 7
Systemic administration of erbB2-specific human lymphocytes prolongs the survival of mice bearing PC BM lesions. (A and B) Survival data of SCID mice bearing established WISH-PC14 bone lesions (n = 10 mice per group) systemically treated with TNP- or erbB2-specific CR–bearing lymphocytes or with medium, without (A) or with (B) preconditioning with 2 Gy TBI.